Guard Therapeutics International (GUARD) Stock Overview
A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GUARD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Guard Therapeutics International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 18.75 |
| 52 Week High | SEK 34.80 |
| 52 Week Low | SEK 11.85 |
| Beta | -0.21 |
| 1 Month Change | 6.84% |
| 3 Month Change | 56.90% |
| 1 Year Change | -36.22% |
| 3 Year Change | -57.87% |
| 5 Year Change | -69.31% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Nov 19
Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky
Apr 18Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely
Jan 04Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely
Sep 20Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans
Apr 06We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Sep 09Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Feb 19We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Aug 17Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth
Apr 19Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Jan 04Shareholder Returns
| GUARD | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.8% | 3.4% | 0.3% |
| 1Y | -36.2% | -4.6% | -3.9% |
Return vs Industry: GUARD underperformed the Swedish Biotechs industry which returned -5.3% over the past year.
Return vs Market: GUARD underperformed the Swedish Market which returned -3.6% over the past year.
Price Volatility
| GUARD volatility | |
|---|---|
| GUARD Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: GUARD has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: GUARD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Tobias Agervald | guardtherapeutics.com |
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.
Guard Therapeutics International AB (publ) Fundamentals Summary
| GUARD fundamental statistics | |
|---|---|
| Market cap | SEK 378.14m |
| Earnings (TTM) | -SEK 115.77m |
| Revenue (TTM) | n/a |
Is GUARD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUARD income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 115.77m |
| Earnings | -SEK 115.77m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GUARD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/15 16:35 |
| End of Day Share Price | 2025/07/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guard Therapeutics International AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Ludvig Svensson | DNB Carnegie Commissioned Research |
| Hans Mähler | Nordea Markets |